Preface: A Career in Nutrition and Cardiovascular Disease: From Research to Results to Public Health Policy by Daan Kromhout
351 PublicHealthReviews,Vol.33,No2,351-362
Preface: 
A Career in Nutrition and Cardiovascular Disease: 
From Research to Results to Public Health Policy
Daan Kromhout, PhD, MSc, MPH1
Key  Words:  Cardiovascular  disease,  coronary  heart  disease,  nutrients,  diet, 
physical activity, smoking, public health policy
Recommended  Citation:  Kromhout  D.  Preface:  a  career  in  nutrition  and 
cardiovascular disease: from research to results to public health policy. Public
HealthReviews. 2012;33:351-62.
BACKGROUND
I began my studies with a Bachelor and a Master of Science in human 
nutrition followed by a PhD from 1974 to 1978. My PhD research was 
focused  on  risk  factors  for  cardiovascular  disease  (CVD)  in  children. 
Together with my colleague Frits van der Haar, we examined 2,500 school 
children measuring their height, weight and skinfold thicknesses in three 
towns in The Netherlands. We determined serum cholesterol and we did a 
dietary survey. In that study we found that five percent of children were 
obese and 25 percent had a higher serum total cholesterol level of more 
than 200 mg/100 ml (5.2 mmol/l).1 This work was all descriptive and at that 
time I became more interested in questions such as what do the percentages 
mean and what is the meaning of high serum cholesterol levels in children? 
Can you translate that into future CVD risk? 
During  my  PhD  project,  I  attended  a  seminar  of  the  International 
Society of Cardiology in Mexico in 1975. There was a stimulating faculty 
at the seminar including Professor Geoffrey Rose from the London School 
of  Hygiene,  Professor  Jeremiah  Stamler  from  Chicago  and  Professor 
Archie Cochrane from Cardiff after which The Cochrane Collaboration is 
named. Jeremiah Stamler gave a great talk about the Seven Countries Study 
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and I discovered in Mexico that the Study also contained a cohort from The 
Netherlands in the town of Zutphen.
I had not previously been told of the Zutphen Study and when I returned 
to the Netherlands I visited my first professor of nutrition, Cees den Hartog, 
and asked if he could tell me something about the Zutphen Study. It turned 
out that he was the Chair of the Advisory Committee for Zutphen and he 
told me that they had a problem because the Principal Investigator, Professor 
Van Buchem, had retired and they could not find anyone to head the study. 
The reason that they could not find someone was that, at that time, there 
was no formal training in epidemiology in The Netherlands and there were 
very few epidemiologists. Den Hartog told me, “If you are interested you 
can start tomorrow.” I was interested in the study, but I was working on my 
PhD and I said that I would first like to finish my thesis. Two years later I 
finished  my  degree  and  moved  from  Wageningen  University  to  the 
University of Leiden to the Institute of Social Medicine as an Assistant 
Professor of Nutrition and Epidemiology. I went back to Professor Den 
Hartog and we agreed that I would begin to work on the Zutphen Study. 
ZUTPHEN AND THE SEVEN COUNTRIES STUDY
The reason that I was interested in Zutphen was that it was the only cohort 
of the 16 in the Seven Countries Study in which detailed information was 
repeatedly (every 5 years) collected on the diet of all the participants. In all 
other cohorts there was only a small sample selected at the baseline survey, 
generally between ten and 50 persons, and those men kept a dietary record 
for seven days. If they could not keep the records themselves, for instance 
of the farmers in Southern Europe some could not write at that time, there 
was a nutritionist who came to the home and collected the information for 
the records. These individuals also collected the equivalent amount of the 
foods they had eaten in containers that were sent to Minneapolis to the 
laboratory of Professor Ancel Keys, the Principal Investigator of the Seven 
Countries Study, for fatty acid analysis.
In Zutphen, the cross-check dietary history method was used to collect 
individual dietary data. In this method the dietician first asks, what is the 
general pattern of food consumption during a usual day? Then, based on 
the list of all foods consumed, it is determined if they are eaten on a daily, 
weekly, or monthly basis. And finally, a cross-check is made with the food 
that was bought for the whole family during a week. From this information, 
an average intake of individual foods is calculated. These are very detailed 
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another four to five hours to integrate the collected material into an average 
food consumption pattern. This is a very intensive process and a dietician 
can only do one person per day. 
When I became the Principal Investigator of the study in 1978 almost 
nothing was computerized. With respect to the dietary history the only 
thing my predecessors had done in terms of analysis of the data was to 
calculate the total amount of energy and the grams of protein, fat and 
carbohydrates. My first job was to code all the dietary data and key them. I 
got some grants from the Nutrition Council and from other organizations to 
start digitalizing all the information. It took me two years before I finished 
that job and only then could I start data analysis. 
In 1980 I got a grant from the Netherlands Organization for Research 
(NWO) to spent a year at the University of Minnesota with the Professors 
Ancel Keys and Henry Blackburn to extend my training in epidemiology 
and public health by following a MPH program. I also started data analysis 
of the Zutphen Study.  Back in Leiden I began my research on diet and 
chronic diseases. This work led to the first paper I had in a high-impact 
journal, a paper on dietary fiber and coronary heart disease (CHD), cancer 
and all cause mortality in Zutphen published in TheLancet in 1982.2 
In the 1980s data analysis of diet-disease relationships in prospective 
cohort studies was very time consuming. Computers were connected to the 
mainframe of the University. For the analysis that I was interested in, the 
relationship between diet and CHD, it was impossible to do the analysis 
during the daytime when the computer was used for simple things like a 
t-test. It was only in the evening or at night that we could run Cox regression. 
If you had made a mistake you came back the next day to correct the 
mistake and you had to wait for the next night. For people who are doing 
research now, it is almost unbelievable how it was done at that time.
As already mentioned, the Zutphen Study is part of the larger Seven 
Countries  Study  initiated  and  directed  by  Professor Ancel  Keys  from 
Minneapolis. He selected 16 cohorts in seven different countries (United 
States, Finland, The Netherlands, Italy, Greece, the former Yugoslavia and 
Japan). In total, 12,753 men aged 40-59 were examined between 1958 and 
1964 and they have been followed for 40 years; currently we are updating 
the 50-year mortality data of the Study. 
The first meeting I had with the investigators of the other countries was 
in 1979 on the island of Crete organized by the Greek colleagues; all the 
Principle Investigators of the studies were there. From that time I became 
involved not only in the Zutphen Study but also the Seven Countries Study. 
For  instance,  I  coordinated  with  my  colleague,  Professor  Alessandro 
Menotti from Italy, the 25-year mortality follow-up. In 1990 we put a 354 PublicHealthReviews,Vol.33,No2
database together in Rome containing risk factor data from the baseline, 
five-year and ten-year follow-up surveys in combination with the 25-year 
mortality data. 
In 1985 I carried out a 25-year follow up of the Zutphen cohort. By that 
time, the men were between the ages of 65 and 84 and it had become a small 
cohort because of the 878 men examined in 1960 about half of them had 
died in 25 years. The original cohort from Zutphen was a random sample of 
men born between 1900 and 1920, so it was possible to add another random 
sample of men born in the same period. In this way I obtained a cohort of 
900 elderly men who have been followed up until now. In the studies in the 
elderly we did not only follow the protocol for CVD epidemiology data 
collection, but also added information about different aspects of health. 
Besides the physical aspect of health, we are also interested in mental and 
social aspects of health. The work was repeated in 1990, 1995 and 2000 and 
thereafter only the mortality follow-up was continued. Similar surveys were 
carried out by my colleagues, Alessandro Menotti in Italy and Aulikki 
Nissinen in Finland. Jointly, we began what we called the Finland, Italy and 
Netherlands Elderly Study (FINE Study), which is the elderly component 
of the Seven Countries Study. Later on, our colleagues from Serbia (Srecko 
Nedeljkovic) and  Crete (Anthony Kafatos) decided to carry out similar 
surveys. So, in total there are nine European cohorts that also have the 
elderly component. The FINE Study was later combined with the SENECA 
Study  (the  Survey  in  Europe  on  Nutrition  in  the  Elderly:  a  Concerted 
Action)  becoming  the  European  Union  funded  Healthy  Ageing:  a 
Longitudinal study in Europe (HALE) project. The combined data provided 
a larger group and the SENECA Study also included elderly women and by 
combining the data the study got a broader perspective.
RESULTS FROM ZUTPHEN AND THE SEVEN COUNTRIES 
STUDIES 
The Seven Countries Study was started by Ancel Keys to show whether the 
risk  factors,  that  were  known  from  and  the  Minnesota  Business  and 
Professional Men Study and the Framingham Study, were also predictive in 
other countries. This was the reason why Keys selected cohorts in the US, 
Northern and Southern Europe, and Japan. The results from the Seven 
Countries Study have shown that the strength of the association of risk 
factors such as serum cholesterol3 and blood pressure4 in relation to CHD 
mortality was similar in the different countries but the absolute risk was 
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event in 25 years in relation to serum cholesterol and blood pressure was 
much  higher  in  the  US  and  Northern  Europe  than  in  Mediterranean 
Southern Europe and Japan. This means that need for treatment of high-risk 
persons is highest in the US and Northern Europe. 
Two of my most frequently quoted papers are on diet and CHD. The 
first was on fish consumption and CHD mortality during 20 years of follow 
up and was published in the NewEnglandJournalofMedicine.6 What I 
found was that men who had been eating fish once or twice a week compared 
with those that did not eat fish had a 50 percent lower relative risk of fatal 
CHD. That was the first publication on fish consumption and CHD mortality 
using data from a prospective cohort study. When I analyzed the data in 
1984  the  only  information  we  had  on  the  subject  was  based  on  the 
comparison between the Inuit and the Danes. It was known that the Inuit 
had an extremely high consumption of seafood (about 400 g/day) and the 
Danes only 60 g/day and the incidence from CHD was ten times lower in 
the Inuit than in the Danes. That was a comparison on the population level 
and there was no information on the individual level. The average intake of 
fish in Zutphen men was only 20 g/day, 20 times lower than in the Inuit! It 
was a great surprise that we found such a strong association at a low level 
of fish consumption.  
The second major finding was on flavonoids and CHD risk. The story 
behind that is that in 1986 I got a request to present a paper on micronutrients 
and cancer for an International Life Sciences Institute (ILSI) conference. 
Besides a literature review, I decided also to analyze the relation between 
diet and lung cancer in the Zutphen Study. I found that vitamin C was 
inversely related to lung cancer even after taking smoking into account. I 
was also interested in which foods were responsible for this association and 
I expected for instance that oranges and potatoes would be protective, 
because these are rich sources of vitamin C. When I did the analysis that 
was not the case; the strongest association was obtained for apples. Then I 
wondered,  what  are  the  bioactive  compounds  in  apples  that  could  be 
responsible for that? 
To make a long story short, I went to Minneapolis to Professor Lee 
Wattenberg, an international renowned expert on anticarcinogens, and he 
suggested that the flavonoids could be the reason for the protective effect, 
because they are very strong anti-oxidants and are present in apples. This 
hypothesis sounded very attractive to me and I applied together with my 
colleague Dr. Peter Hollman for a grant for a PhD student to research 
flavonoids, working with the hypothesis that flavonoids would be protective 
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lung  cancer  or  total  cancer  in  the  Zutphen  Study. We  then  decided  to 
analyze flavonoids also in relation to CHD, based on the hypothesis that 
anti-oxidants could prevent the oxidation of LDL cholesterol and could 
therefore be protective. In this case we found a strong inverse association 
between flavonoid intake and CHD and that was published in TheLancet.7
There are many more results from the Zutphen and Seven Countries 
Study.  Alessandro  Menotti,  Henry  Blackburn  and  I  wrote  a  book 
summarizing the results of the Seven Countries Study over the first 35 years 
of follow-up.5 The book covers the major risk factors, diet and lifestyle 
factors, such as physical activity, smoking and alcohol in relation to CHD. 
THE ALPHA OMEGA TRIAL
One of my main interests since the beginning of my career is the relation 
between fatty acids and CHD. When I found for the first time the inverse 
association between fish consumption and fatal CHD I wanted to replicate 
the  results  obtained  in  Zutphen.  We  found  similar  results  in  three 
independent cohort studies. I am also very much interested in the question 
whether associations obtained in prospective cohort studies are causal. I 
had  kept  up  correspondence  with  Professor Archie  Cochrane  after  the 
seminar in Mexico in 1975 and he always said to me that when I would like 
to become a real epidemiologist I had to carry out a randomized control 
trial (RCT). It took quite some time, but I eventually received funding from 
the Netherlands Heart Foundation, the National Institutes of Health in the 
US and Unilever Research in The Netherlands for a large RCT on omega-3 
fatty acids and CHD in order to show that these fatty acids are the nutrients 
responsible for the protective effect of fish consumption. 
I designed the Alpha Omega Trial in myocardial infarction patients who 
were randomized to receive four different types of margarines, using a 2 x 
2 factorial design. The margarines were identical in taste, color, odor and 
texture. One group received, on a daily basis, on average an additional 
amount of 400 mg of the omega-3 fatty acids, eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA) (about the equivalent of eating fish twice 
a week). The second group received an additional 2 g of alpha-linolenic 
acid, a plant-based precursor of EPA-DHA found in plant oils such as 
soybean and linseed oil and could be a substitute to fish consumption if 
found to have an effect. The third group received a combination of both 
EPA-DHA and alpha-linolenic acid and the fourth a placebo. It was the first 
double-blind placebo-controlled trial with CVD endpoints and it lasted for 
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In 2010, we published in the NewEnglandJournalofMedicine the 
main results from the trial in which we did not find an effect of omega-3 
fatty acids on different CVD endpoints.8 Probably the reason for this was 
that the participants in the trial were all post-myocardial infarction patients 
with  well-controlled  cardiovascular  risk  factors;  90  percent  received 
antihypertensives, 85 percent statins and 98 percent antithrombotics. So it 
was a very well-treated population that was at a low risk for new CVD 
events, which is most likely the reason that we did not find an effect. This 
highlights  that  it  is  extremely  difficult  in  nutritional  research  to  show 
causality. Starting with the association of fish consumption and fatal CHD, 
then pinpointing the omega-3 fatty acids, and finally proving that they are 
causally related is a very difficult task. 
Recently, we published a paper in DiabetesCare in which we described 
the results of a subgroup analysis in patients who, besides having had a 
myocardial infarction, also had diabetes. In that group we did show a strong 
protective  effect  of  omega-3  fatty  acids  on  the  composite  endpoint  of 
sudden  death,  cardiac  arrest  and  the  implantation  of  cardioverter-
defibrillators (ICDs).9 The reason is that patients who have had a myocardial 
infarction and in addition have diabetes are at high risk for this endpoint. 
These results are in accord with those of older secondary prevention trials 
in which treatment of cardiovascular risk factors was at a much lower level 
than nowadays. This demonstrates that changes in treatment during a period 
of more than 20 years should be taken into account in interpreting the 
results of trials.
TRANSLATING RESEARCH INTO PUBLIC HEALTH PRACTICE
The next question to be addressed should be how the results of research 
should be translated into public health practice. The case of fish consumption 
and fatal CHD is a very interesting one because not only the Alpha Omega 
Trial was negative, but at almost the same time the results of two other 
negative trials, the OMEGA trial from Germany and the SU.FOL.OM3 
trial from France, were published. So if you have to advise the general 
population on fish consumption you are in a complex situation. The results 
of the prospective cohort studies show a clear inverse relation of eating fish 
once or twice a week with fatal CHD. Older trials confirmed the inverse 
association of fish consumption and fatal CHD, but the most recent trials 
did not show an effect except in subgroups. How do you integrate all the 
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To my opinion the totality of evidence should be evaluated. A meta-
analysis  published  in  2006  by  Mozaffarian  and  Rimm  from  Harvard 
combined the results from the prospective cohort studies and the trials. 
They  showed  that  250  mg/day  of  EPA-DHA  was  enough  to  provide 
protection from fatal CHD compared to not eating fish. Therefore, the 
advice is to eat fish once or twice a week. Meanwhile, the information from 
the recent trials that were negative can be explained by the fact that the 
patients in these trials were at a much lower absolute risk compared to the 
patients in the older trials. The problem is that in low-risk patients it is very 
difficult to show significant reductions in risk. 
The negative results of the recently published trials on the effect of 
omega-3 fatty acids led to an intense debate among researchers. Based on 
the inconsistent results of the trials carried out so far, several colleagues 
concluded  that  in  that  case  a  public  health  recommendation  on  fish 
consumption can’t be given. However, my view is that taking into account 
all the evidence on the omega-3 fatty acids and CHD, the advice to eat fish 
once or twice a week for prevention of CHD is justified. 
TRANSFORMING INFORMATION INTO POLICY: ROLES AT THE 
NATIONAL INSTITUTE OF PUBLIC HEALTH AND THE HEALTH 
COUNCIL OF THE NETHERLANDS
The National Institute for Public Health (started 100 years ago with a focus 
on infectious diseases) is funded by the Ministry of Public Health. In the 
late 1980s when I started there, the Ministry became interested in the 
relation between lifestyle and chronic diseases. The Ministry asked the 
Institute in the 1990s to prepare a report about the state of health and 
possible future developments. What we did in the first document was to 
determine what the most important diseases were in the Netherlands from 
a public health perspective. After a lot of discussion we described the ten 
most important diseases from a mortality, prevalence and quality of life 
perspective. Our analysis showed that CVD, cancer and lung diseases are 
the most important in terms of mortality. However, from the point of view 
of the prevalence, chronic diseases such as diabetes and osteoarthritis are 
important and from a quality of life perspective, mental disorders such as 
anxiety disorders and depression could be added. 
So what we tried to do was to get an overall picture of the major health 
problems in the country and we also tried to forecast what the important 
health problems would be in the next 20 years. If you take CVD for instance, 
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more than 40 percent during that period. That sounds peculiar, because 
CVD mortality data show a continuous decrease in The Netherlands and in 
many  western  countries  since  the  early  1970s. Thus,  from  a  mortality 
standpoint,  CVD  are  becoming  less  important.  However,  in  terms  of 
prevalence i.e., burden of disease CVD are becoming more important. This 
dichotomy,  especially  in  the  beginning,  was  not  well  understood.  The 
public health reports were instrumental in clarifying complex issues for 
policy makers and to get a clear picture of what is going on in their country 
in terms of the burden of diseases. 
Another  important  issue  is,  can  you  prevent  chronic  diseases?  We 
calculated  how  many  people  in The  Netherlands  died  due  to  cigarette 
smoking, to a poor diet, to physical inactivity, etc. From our work in the 
1990s it became clear that of the total mortality in The Netherlands (which 
on a yearly basis is about 140,000) about 20,000 deaths could be attributed 
to smoking. We defined diet in terms of quantity and quality. The prevalence 
of obesity was used as an indicator of quantity and two nutrients (saturated 
and trans fat) and three foods (fish, fruit and vegetables) as indicators of 
quality. These two indicators for diet could explain a substantial part of the 
occurrence of chronic diseases. So we showed policy makers the importance 
of prevention and in later reports we also described the health care cost of 
the different diseases. This provided to policy makers information on which 
diseases  were  most  costly  to  society  and  they  could  take  this  type  of 
information into account in decision making.
While  I  was  at  the  National  Institute  for  Public  Health,  the  final 
document that we put together was a report on diet called Our Food Our 
Health in which we integrated the information on diet and chronic diseases 
along with information on toxicological and microbiological aspects of 
foods. We showed that the potential health gain of changes from current 
diet to a diet based on the Guidelines for a Healthy Diet from the Health 
Council was much larger than the health gain from improvements on the 
microbiological and the toxicological aspects of foods. The reason for that 
document was to find out which measures in relation to the different aspects 
of food provided the largest health gain.  
CONCLUSIONS
Research on diet and CVD and diet and health in general has been focused 
on nutrients and bioactive compounds. Personally, I became more and 
more interested in the health effects of foods and the total diet, because if 
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message in terms of foods and not in nutrients. Therefore, information on 
the associations of foods with different health outcomes are extremely 
important. If you tell to people who are interested in CVD prevention that 
they should not consume more than ten percent of energy from saturated 
fat, that message will not be understood because in that case they need to 
have knowledge about what saturated fat is, which foods are rich sources of 
saturated fat, etc. I think the integration of information on the health effects 
of  nutrients  and  foods  in  prototypes  of  healthy  diets  is  of  paramount 
importance for prevention of chronic diseases. We found in the HALE 
project, a strong protective effect of a Mediterranean style diet, not only in 
relation to CHD and CVD but also to all-cause mortality.10
What I also want to stress is not only to focus on nutrients, foods and 
diets but also on other lifestyles factors like physical activity and smoking. 
My  thinking  about  those  lifestyle  factors  has  become  more  and  more 
integrated over time. So in terms of translating research to policy, I think, 
knowing what the health effects of foods are, is extremely important from 
a policy perspective. However, at the same time I like to know from a 
scientific point of view which nutrients or bioactive compounds are causing 
the inverse associations of e.g., fish and cocoa with CVD.6,11 
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Acronyms List:
CHD = Coronary heart disease
CVD = Cardiovascular disease
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